Zacks.com on MSN4h
CTLT Stock Falls as Potential Hindrance to NVO Buyout Deal Increases
Catalent stock faces uncertainty as several pharma companies voice concern about potential limited competition following the ...
Lilly to launch Mounjaro in rival Novo Nordisk's home country: report
Eli Lilly (LLY) is reportedly preparing to launch Mounjaro in Denmark, the home country of its leading rival in the ...
Novo Nordisk's semaglutide could also be effective against Alzheimer's
A new study is adding to evidence that GLP-1 drugs such as Novo Nordisk's semaglutide and Eli Lilly's tirzepatide could also ...
Ozempic can even cut the risk of Alzheimer’s disease, study says
Novo Nordisk’s blockbuster drug Ozempic (NVO) is linked to yet another health benefit. This time it’s lowering the risk of ...
Ozempic Can Potentially Cut Risk Of Alzheimer's Compared To Other Diabetic Medicines, Study Shows
Semaglutide, found in Novo Nordisk's Ozempic, may reduce Alzheimer's risk in type 2 diabetes patients, per new research. FDA ...
Novo Nordisk asks FDA to ban cheap copies of Wegovy, Ozempic, CNBC reports
Novo Nordisk (NVO) has asked the FDA to ban cheap copies of its weight loss drugs Wegovy and Ozempic, arguing they pose safety risks, ...
Hims & Hers Stock Dropped: Here's What You Need to Know
Hims & Hers (NYSE: HIMS) fell as much as 12% in trading on Wednesday after pharmaceutical company Novo Nordisk (NYSE: NVO) ...
Ozempic And Wegovy Maker Novo Nordisk Asks FDA To Halt Production Of Compounded Fat Loss Drugs Due To Their 'Inherent Complexity'
Novo Nordisk NVO has appealed to the U.S. Food and Drug Administration (FDA) to halt the production of compounded versions of ...
Nvidia Launches Danish Sovereign AI Supercomputer That Novo Nordisk Will Use
Pharmaceutical giant Novo Nordisk plans to use Denmark's first sovereign artificial intelligence supercomputer—powered by ...
Stocks on Sale Include Enphase, HIMS, and Seagate
On Wednesday, Enphase Energy (ENPH) traded at lows not seen in a year. ENPH stock fell by 14.9% to close at $78.47. In the third quarter, Enphase reported a 30.9% Y/Y drop in revenue to $380.87 ...
Study finds high costs, few benefits associated with GLP-1 weight loss drugs
A new study from a pharmacy benefit manager is casting doubt on the benefits of GLP-1 drugs used for weight loss, finding ...
Exclusive-Weight-loss drugs didn't curb health costs within two years, data show
The full-year cost of care for U.S. patients with obesity two years after starting on Novo Nordisk’s Wegovy or similar GLP-1 ...